These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 12465082)
21. The relationship between akathisia and subjective tolerability in patients with schizophrenia. Kim JH; Byun HJ Int J Neurosci; 2010 Jul; 120(7):507-11. PubMed ID: 20583904 [TBL] [Abstract][Full Text] [Related]
22. Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome. Lee JW Ann Clin Psychiatry; 2007; 19(1):9-16. PubMed ID: 17453656 [TBL] [Abstract][Full Text] [Related]
23. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Inada T; Beasley CM; Tanaka Y; Walker DJ Int Clin Psychopharmacol; 2003 Jan; 18(1):39-48. PubMed ID: 12490774 [TBL] [Abstract][Full Text] [Related]
24. Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models. Casey DE Br J Psychiatry Suppl; 1996 May; (29):32-9. PubMed ID: 8733821 [No Abstract] [Full Text] [Related]
25. Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Maat A; Fouwels A; de Haan L Psychopharmacol Bull; 2008; 41(3):5-10. PubMed ID: 18779773 [TBL] [Abstract][Full Text] [Related]
26. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. Casey DE Psychiatr Clin North Am; 1993 Sep; 16(3):589-610. PubMed ID: 8105453 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716 [TBL] [Abstract][Full Text] [Related]
29. Drug-induced movement disorders in institutionalised adults with mental retardation: clinical characteristics and risk factors. Sachdev P Aust N Z J Psychiatry; 1992 Jun; 26(2):242-8. PubMed ID: 1353672 [TBL] [Abstract][Full Text] [Related]
30. [Three-dimensional ultrasonic movement analysis of gait and hand-movements in schizophrenic patients]. Putzhammer A; Perfahl M; Pfeiff L; Müller JL Psychiatr Prax; 2005 Apr; 32 Suppl 1():S38-42. PubMed ID: 15818519 [TBL] [Abstract][Full Text] [Related]
31. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Ganzini L; Casey DE; Hoffman WF; McCall AL Arch Intern Med; 1993 Jun; 153(12):1469-75. PubMed ID: 8512437 [TBL] [Abstract][Full Text] [Related]
32. Akathisia in adults with mental retardation: development of the Akathisia Ratings of Movement Scale (ARMS). Bodfish JW; Newell KM; Sprague RL; Harper VN; Lewis MH Am J Ment Retard; 1997 Jan; 101(4):413-23. PubMed ID: 9017087 [TBL] [Abstract][Full Text] [Related]
33. Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism. Caligiuri MP; Teulings HL; Filoteo JV; Song D; Lohr JB Hum Mov Sci; 2006 Oct; 25(4-5):510-22. PubMed ID: 16647772 [TBL] [Abstract][Full Text] [Related]
34. Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP). Higa M; Ohnuma T; Maeshima H; Hatano T; Hanzawa R; Shibata N; Sakai Y; Suzuki T; Arai H Neurosci Lett; 2010 Jan; 469(1):55-9. PubMed ID: 19931593 [TBL] [Abstract][Full Text] [Related]
35. Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia. Gebhardt S; Härtling F; Hanke M; Theisen FM; von Georgi R; Grant P; Mittendorf M; Martin M; Fleischhaker C; Schulz E; Remschmidt H Eur Child Adolesc Psychiatry; 2008 Feb; 17(1):44-53. PubMed ID: 17876506 [TBL] [Abstract][Full Text] [Related]
36. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms. Taniguchi T; Sumitani S; Aono M; Iga J; Kinouchi S; Aki H; Matsushita M; Taniguchi K; Tsuno M; Yamanishi K; Tomotake M; Kaneda Y; Ohmori T Hum Psychopharmacol; 2006 Oct; 21(7):439-45. PubMed ID: 17029303 [TBL] [Abstract][Full Text] [Related]
37. Pathophysiology of antipsychotic drug-induced movement disorders. Casey DE J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109 [TBL] [Abstract][Full Text] [Related]
38. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584 [TBL] [Abstract][Full Text] [Related]
39. The inter-relationships of tardive dyskinesia, parkinsonism, akathisia and tardive dystonia: the Curaçao Extrapyramidal Syndromes Study II. van Harten PN; Hoek HW; Matroos GE; Koeter M; Kahn RS Schizophr Res; 1997 Aug; 26(2-3):235-42. PubMed ID: 9323356 [TBL] [Abstract][Full Text] [Related]
40. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Weiden PJ; Mann JJ; Haas G; Mattson M; Frances A Am J Psychiatry; 1987 Sep; 144(9):1148-53. PubMed ID: 2888321 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]